ZIMV
ZimVie Inc.18.99
+0.00+0%
Oct 17, 4:00:00 PM EDT
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
535.72MP/E (TTM)
-Basic EPS (TTM)
-0.69Dividend Yield
0%Recent Filings
8-K
ZimVie goes private at $19/share
ZimVie completed its merger with ARCHIMED-backed Parent on October 20, 2025, becoming a privately held company after shareholders received $19.00 per share in cash. The firm terminated its prior JPMorgan credit agreement, entered a new first lien facility with Golub Capital, and delisted from Nasdaq effective October 30. ARCHIMED eyes accelerated growth. Board and officers fully turned over.
8-K
Merger approved, closing soon
10-Q
Q2 FY2025 results
ZimVie held Q2 net sales flat at $116.7M y/y despite volume dips in implants and biomaterials, yet swung to $1.3M operating profit from a $6.7M loss through manufacturing efficiencies and lower SG&A. Gross margin expanded to 64.6% (derived) from 62.7%, while diluted EPS from continuing operations improved to $(0.14) from $(0.35), consistent with 28.0M weighted shares. Cash sits at $70.2M with $221.9M term debt due 2027 and full $175M revolver availability; acquired Costa Rica dental distributor in April 2025 for $3.3M (customer relationships amortized over 10 years). July merger deal at $19/share awaits approvals. Spine divestiture wrapped up. Tariffs threaten Spain manufacturing costs.
8-K
ZimVie acquisition announced
ZimVie entered a definitive agreement on July 21, 2025, to be acquired by an ARCHIMED affiliate for $19.00 cash per share, expected to close year-end pending stockholder and regulatory nods. Q2 net sales dipped 0.1% to $116.7M, yet net loss narrowed to $(3.8)M from $(9.6)M prior year; Adjusted EBITDA climbed to $17.5M. Acquisition risks stockholder rejection.
8-K
ZimVie merger at $19/share
ZimVie signed a merger deal on July 20, 2025, to go private via acquisition by an ARCHIMED affiliate, paying shareholders $19.00 per share in cash for an enterprise value of ~$730 million. Board unanimously approved; 40-day go-shop ends August 29, with stockholder and antitrust nods needed by year-end 2025. Deal holds financing certainty. Risks loom if approvals fail.
AORT
Artivion, Inc.
45.91+0.54
BVS
Bioventus Inc.
7.52+0.02
ENOV
Enovis Corporation
26.07-0.47
NVST
Envista Holdings Corporation
21.90-0.16
SIBN
SI-BONE, Inc.
19.42+1.01
SOLV
Solventum Corporation
80.59-1.30
TUTH
Standard Dental Labs Inc.
0.30-0.01
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52
ZOMDF
Zomedica Corp.
0.11+0.00